PMID: 6985269Oct 1, 1982Paper

Inhibition of in vitro natural killer activity by the third component of complement: role for the C3a fragment

Proceedings of the National Academy of Sciences of the United States of America
C CharriautR Frade

Abstract

Purified human native third component of complement, C3, was found to inhibit in vitro natural killer (NK) cell cytotoxicity in both mouse and human systems. The effect was dose and time dependent, a 50% inhibition being reached with 190 nM C3 (35 micrograms/ml) added during the NK assay or after a 30-min preincubation of the effector cells with this C3 concentration. C3 was shown to act at the effector-cell population level because pretreatment of the target cells did not modify the NK lysis. The inhibition was not due to general cytotoxicity nor to cell agglutination. Moreover, another in vitro cytotoxicity system (represented by alloreactive cytotoxic lymphocytes) was not affected by purified C3. Structural analysis of the active part of the C3 molecule shows that the C3-induced inhibition is supported by the C3a fragment. Release of carboxyl-terminal arginine residue by carboxypeptidase B, converting C3a into des-Arg77-C3a, did not alter the inhibitory effect displayed by this fragment. These results suggest that C3a may play an important role in the regulation of NK activity.

References

Aug 15, 1975·International Journal of Cancer. Journal International Du Cancer·R B HerbermanD H Lavrin
Jul 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·S K Law, R P Levine
Jan 1, 1979·Immunological Reviews·R Kiessling, H Wigzell
Feb 1, 1967·Proceedings of the Society for Experimental Biology and Medicine·V J StecherG J Thorbecke
Oct 1, 1973·European Journal of Immunology·M H JuliusL A Herzenberg
Jun 1, 1981·The Journal of Experimental Medicine·D T FearonG G Thomson
Jan 1, 1980·Journal of Immunological Methods·T Timonen, E Saksela

❮ Previous
Next ❯

Citations

Jan 1, 1985·Immunology Letters·Z Fishelson
Dec 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·G F BurnsI R Mackay
Aug 1, 1983·The Journal of Experimental Medicine·M J Polley, R L Nachman
Mar 31, 2010·Seminars in Hematology·George J Weiner
Oct 8, 2015·Critical Reviews in Oncology/hematology·Narges SeyfizadehSara Huerta-Yepez
Oct 30, 2008·Clinica Chimica Acta; International Journal of Clinical Chemistry·Kathleen DeiterenAnne Marie Lambeir
Apr 27, 2012·European Journal of Immunology·Xiaoping QingJane E Salmon
May 20, 2015·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Jing WuKatherine Cianflone
Oct 18, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Karen FrancisPhilippe Gasque
Oct 18, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Stefanie DererThomas Valerius
Jan 24, 2003·The Journal of Biological Chemistry·David KalantPeter N Monk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Antibodies: Agglutination

Antibody-mediated agglutination is the clumping of cells in the presence of antibody, which binds multiple cells together. This enhances the clearance of pathogens. Find the latest research on antibody-mediated agglutination here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.